Price
$1.32
Increased by +3.94%
Dollar volume (20D)
215.23 K
ADR%
10.32
Earnings report date
May 15, 2025
Shares float
12.29 M
Shares short
255.35 K [2.08%]
Shares outstanding
15.78 M
Market cap
17.67 M
Beta
0.33
Price/earnings
N/A
20D range
0.81 1.36
50D range
0.61 1.40
200D range
0.40 1.40

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.

The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.

It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.

ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.

The company is based in Fremont, California.

ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 13, 24 -0.01
Increased by +98.17%
-
Aug 14, 24 -0.09
Increased by +86.93%
-
May 17, 24 -0.40
Decreased by -573.33%
-
Mar 13, 24 -0.39
Decreased by -161.20%
-
Nov 15, 23 -0.82
Decreased by -643.73%
-0.04
Decreased by -1.95 K%
Aug 14, 23 -0.68
Decreased by -1.04 K%
-0.06
Decreased by -1.04 K%
May 15, 23 -0.06
Increased by +70.00%
-0.05
Decreased by -20.00%
Mar 31, 23 -0.15
Increased by +51.61%
-0.15
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 1.97 K
Increased by +63.15%
229.30 K
Increased by +105.83%
Increased by +11.66 K%
Increased by +103.57%
Dec 31, 24 1.97 K
Decreased by -9.19%
229.30 K
Increased by +107.37%
Increased by +11.66 K%
Increased by +108.12%
Sep 30, 24 389.28 K
Increased by +2.35 K%
-186.56 K
Increased by +94.38%
Decreased by -47.93%
Increased by +99.77%
Jun 30, 24 117.14 K
Increased by +1.82 K%
-1.01 M
Increased by +55.26%
Decreased by -864.46%
Increased by +97.67%
Mar 31, 24 1.21 K
Decreased by -99.06%
-3.93 M
Decreased by -5.25 K%
Decreased by -326.39 K%
Decreased by -569.24 K%
Dec 31, 23 2.17 K
Decreased by -99.63%
-3.11 M
Increased by +30.88%
Decreased by -143.69 K%
Decreased by -18.70 K%
Sep 30, 23 15.88 K
Decreased by -62.42%
-3.32 M
Increased by +12.15%
Decreased by -20.89 K%
Decreased by -133.77%
Jun 30, 23 6.11 K
Decreased by -98.05%
-2.26 M
Decreased by -16.24%
Decreased by -37.05 K%
Decreased by -5.85 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY